Would you like one of our team to contact you? Enter your contact details and we’ll be in touch soon!

Would you like to see how quickly you can answer your research questions using the Euretos Knowledge Platform? Enter your contact details and we’ll set up a demo to show you!

We provide a consultancy service where we create a report tailored to you research question. Just let us do the work for you! Enter your contact details and we’ll contact you to discuss next steps. Faster.




Order a Report
Book a Demo
Contact
Us
News
FIND DRUGGABLE, SAFE
AND EFFECTIVE TARGETS

FASTER

Thank you for your research question! Enter your details
so we can help you get answers. Faster.




Target
Identification

Accelerate drug discovery. Find novel high value target candidates that have never before been associated with the disease.
Faster.



TARGET IDENTIFICATION EXAMPLE

HOW IT'S DONE
logo

Efficacy, Druggability & Safety

Leverage our millions of gene annotations and combine these with your personal data. Broaden your understanding of the underlying disease mechanisms to find novel target candidates. Then find the best therapeutic targets by assessing candidates simultaneously on multiple key aspects of Efficacy, Druggability & Safety.

Drug Discovery, Accelerated



targetimg

Summary of Target Identification Capabilities

Create and upload gene lists - Leverage the millions of gene annotations in the platform to find candidate targets that meet very specific criteria. Upload your own gene expression and annotation lists to include in your analysis.

Broaden your understanding of the disease mechanism - Overlay multiple gene lists, each associated with specific disease characteristics, to find the most highly involved genes. Discover novel aspects of the disease mechanism (such as associated pathways, metabolites, molecular mechanisms etc) through embedded analytics algorithms.

Assess druggability - in particular known compounds with relevant mode of action (i.e. agonist for down regulated targets) and affinity levels (at least 100Nm), the Human Protein Atlas drug candidate assessment and whether a target is already an FDA approved drug target.

Assess Safety - in particular baseline expression for expression specificity, the number of genetic interactions with the target (and genes involved) and the number of diseases the target is associated with (and the specific diseases involved).

Assess Efficacy - in particular differential expression, functional association with the disease, the number of disease annotations for known gene variants, the number of publications in which the target and the disease co-occur and the number of physiological processes associated with the target that are regarded as hallmarks of cancer (for neoplastic targets only).

Review efficacy for novel targets where no literature (yet) exists In many cases the suggested targets are entirely novel for the disease and only linked through experimental data such as differential expression. The platform provides all indirect relations for the target – disease association including an assessment of the strength of biological interaction. This provides a unique a powerful way to assess efficacy immediately and expand the scope of your target identification activities.